Disc Medicine Inc. (IRON) - Total Assets
Based on the latest financial reports, Disc Medicine Inc. (IRON) holds total assets worth $630.46 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Disc Medicine Inc.'s book value for net asset value and shareholders' equity analysis.
Disc Medicine Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Disc Medicine Inc.'s total assets have evolved over time, based on quarterly financial data.
Disc Medicine Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Disc Medicine Inc.'s total assets of $630.46 Million consist of 99.4% current assets and 0.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 38.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Disc Medicine Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IRON stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Disc Medicine Inc.'s current assets represent 99.4% of total assets in 2024, an increase from 60.9% in 2020.
- Cash Position: Cash and equivalents constituted 38.7% of total assets in 2024, down from 54.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Disc Medicine Inc. Competitors by Total Assets
Key competitors of Disc Medicine Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Disc Medicine Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 23.45 | 19.36 | 0.20 |
| Quick Ratio | 23.45 | 19.36 | 0.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $600.42 Million | $467.68 Million | $-19.81 Million |
Disc Medicine Inc. - Advanced Valuation Insights
This section examines the relationship between Disc Medicine Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.68 |
| Latest Market Cap to Assets Ratio | 4.25 |
| Asset Growth Rate (YoY) | 35.0% |
| Total Assets | $496.77 Million |
| Market Capitalization | $2.11 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Disc Medicine Inc.'s assets at a significant premium (4.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Disc Medicine Inc.'s assets grew by 35.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Disc Medicine Inc. (2020–2024)
The table below shows the annual total assets of Disc Medicine Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $496.77 Million | +34.99% |
| 2023-12-31 | $368.00 Million | +83.81% |
| 2022-12-31 | $200.21 Million | +116.65% |
| 2021-12-31 | $92.41 Million | +1010.84% |
| 2020-12-31 | $8.32 Million | -- |
About Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associ… Read more